EssilorluxotticaESLOF -0.56%82 Debt-to-EBITDA is 2.41 as of Dec. 2025, which is 15% above its 10-year median of 2.09. GuruFocus rates ESLOF with a GF Score™ of 82/100 and a GF Value™ of $273.72 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Essilorluxottica ranks worse than 59.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Essilorluxottica's Debt-to-EBITDA or its related term are showing as below:
ESLOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.01 Med: 2.09 Max: 4.56
Current: 2.18
During the past 13 years, the highest Debt-to-EBITDA Ratio of Essilorluxottica was 4.56. The lowest was 1.01. And the median was 2.09.
ESLOF's Debt-to-EBITDA is ranked worse than 59.4% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs ESLOF: 2.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Essilorluxottica Debt-to-EBITDA Related Terms
Essilorluxottica Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Essilorluxottica's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESLOF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Essilorluxottica's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essilorluxottica Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Essilorluxottica's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Essilorluxottica's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Essilorluxottica (ESLOF) has a Debt-to-EBITDA of 2.41 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Essilorluxottica. This is 15% above median its historical median of 2.09. Over the past decade, Essilorluxottica's Debt-to-EBITDA has ranged from 1.01 to 4.56. According to the industry distribution chart, Essilorluxottica ranks #278 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 59.4%.
Is Essilorluxottica's Debt-to-EBITDA too high?
Essilorluxottica's current Debt-to-EBITDA of 2.41 is 15% above median its 10-year median of 2.09. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 4.56. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Essilorluxottica's value of 2.41 is 55% above this industry median. Based on the distribution chart, Essilorluxottica ranks #278 out of 468 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Essilorluxottica has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essilorluxottica's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Essilorluxottica ranks #278 out of 468 companies for Debt-to-EBITDA. This places Essilorluxottica in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. Essilorluxottica's value of 2.41 is 55% above this benchmark. Historically, Essilorluxottica's own Debt-to-EBITDA has ranged from 1.01 to 4.56 over the past decade. While the company's 10-year median is 2.09 vs. the industry median of 1.56, Essilorluxottica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essilorluxottica's current Debt-to-EBITDA of 2.41 is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Essilorluxottica. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essilorluxottica's current Debt-to-EBITDA is 2.41, which is 15% above median its own 10-year median of 2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essilorluxottica stock overvalued right now?
Based on GuruFocus' analysis, Essilorluxottica (ESLOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $273.72, compared to a current price of $194.75 — trading 28.9% below its estimated fair value. The current Debt-to-EBITDA is 2.41, which is 15% above median its 10-year median of 2.09 and 55% above the Medical Devices & Instruments industry median of 1.56. Essilorluxottica's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Essilorluxottica (ESLOF), the current Debt-to-EBITDA is 2.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essilorluxottica (ESLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Essilorluxottica stock appears to be undervalued.
The current stock price of $194.75 is trading 28.9% below its estimated GF Value™ of $273.72.
GuruFocus considers Essilorluxottica to be Modestly Undervalued.
Key valuation signals for ESLOF:
Debt-to-EBITDA: 2.41 (15% above median its 10-year median of 2.09)
GF Value™: $273.72 vs. price of $194.75 (28.9% below fair value)
Industry Position: 55% above the Medical Devices & Instruments median (#278 of 468)
No single metric tells the full story. See the ESLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EssilorLuxottica is a combination of the leading manufacturer of premium frames and sunglasses and the leading manufacturer of optical lenses. Both companies are significantly larger than the next biggest competitor and command over 15% of the fragmented global eyewear market. The company has a broad geographical presence, with around 37% of sales in Europe, 45% in North America, and the rest in Asia and Latin America.
82GF Score
Get the complete analysis for ESLOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESLOF has been successfully added to your 
